In this review
Start with the bill the household can carry
TMates combines a medication offer with ongoing support and free shipping. Its default injectable one-month cards list semaglutide at $249 and tirzepatide at $297. That is an understandable starting comparison for someone trying to put clinical contact and medicine into the same budget. [1] [2]
I would settle the actual chosen prescription, supply and final charge before comparing discounts. The convenience of a bundled description matters only if the household can use the support and manage the payment without sacrificing other appointments or ordinary costs.
The annual number is a different purchase
The twelve-month semaglutide option is listed at $1,900, displayed as $158 per month; tirzepatide is $1,999, displayed as $167. Three- and six-month options sit between those totals and the one-month plan. As with Lttl’s prepaid plans, the monthly equivalent describes a longer purchase. A one-month trial has its own price. [1] [2]
The cards do not fully explain payment timing or renewal. The terms contemplate payment plans, so I would establish whether the selected total is due now or in installments, and what remains owed after cancellation. Boston Medical Group lists renewal intervals for its longer plans, so compare when the next payment is due and how to stop it before committing to either service. [3]
Know who will handle a difficult week
The general programme FAQ describes telemedicine visits, coaching and medication. TMates’ terms make independent clinicians responsible for medical care. That division can work, provided the reader knows how to reach the treating team and which questions belong with the dispensing pharmacy. [3] [4]
I would compare the actual follow-up frequency and any extra monitoring charges with the selected quote. An attractive support description should translate into a usable care arrangement, rather than leave a reader with only an order-tracking route when a clinical concern needs attention.
Canceling later does not undo every charge
TMates’ published terms give a full refund before medical-history review. They also give one when review finds no qualifying medication-assisted weight-loss plan. Once an eligible patient’s prescription is written and transmitted to a pharmacy, the terms say there is no refund. [3]
That cutoff is more useful than the short cancel-anytime line beside the product. If a refund is not approved, payment plans remain in place. Before paying for a longer term, keep the applicable cancellation deadline, refund stage and remaining balance with the agreement; do not assume unused time always returns as cash. [1] [3]
A medication name does not settle the preparation
The pages identify compounds and offer oral and injectable choices. Strut’s oral and injectable options provide another service to compare, but TMates’ default injection price does not establish the oral preparation or its charge. Nor do promotional comparisons show that a different preparation produces the same result as an approved branded medicine. [1] [2]
FDA says compounds are not approved generic drugs. The clinician needs to explain why the proposed preparation fits the individual situation. The general insurance FAQ also does not establish reimbursement for this plan; TMates’ terms leave uncovered costs with the patient. Keep that possibility out of an optimistic monthly budget. [3] [4] [5]
Choose useful support before a bigger commitment
TMates belongs in a comparison for readers who want coordinated prescribing support and can obtain a clear purchase agreement. Its patient stories should not be used to predict a particular change in weight or to decide which preparation is appropriate. The continuing relationship is what the service must make useful.
Found is a separate clinical and behavioral option to consider when that support is important. Sprout supplies another bundled-care comparison. Compare what each would actually do for the reader, including the financial exit, rather than pick the programme with the smallest equivalent printed on a long-plan card.
Understanding the cost
Default injectable semaglutide: one month $249; three months $650; six months $1,050; twelve months $1,900 ($158/month displayed equivalent). Injectable tirzepatide: one month $297; three months $800; six months $1,299; twelve months $1,999 ($167/month equivalent). Confirm actual debit schedule, supply, renewal and any separate clinical costs. Oral option pricing is not established by the injectable default. [1] [2] [3]
Build your cost estimateSources
- TMates: injectable semaglutide plans and product scope
- TMates: injectable tirzepatide plans and product scope
- TMates: August 12, 2025 care, payment and refund terms
- TMates: care process, programme scope and insurance FAQ
- FDA: compounding, approval and patient medical needs
This review evaluates public service information. It does not claim patient enrollment, product testing or measurement of clinical outcomes.